Regulation of mRNA expression of the SMN2 gene by histone deacetylase inhibitors and their influence on the phenotype of type I and II spinal muscular atrophy;Ovlivnění exprese mRNA genu SMN2 inhibitory histonových deacetyláz a jejich vliv na fenotyp spinální svalové atrofie I. a II. typu

Ceska a Slovenska Neurologie a Neurochirurgie

Volumn 70, Issue 4, 2007, Pages 413-418

  Vondráček, Petr ^a   Zapletalova E ^a   Oslejskova H ^a   Mlcakova L ^a   Fajkusova L ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Hammersmith scale; Histone deacetylase inhibitors; Phenylbutyrate; SMN (survival motor neuron) gene; Spinal muscular atrophy; Valproic acid

Indexed keywords

4 PHENYLBUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SURVIVAL MOTOR NEURON PROTEIN; VALPROIC ACID;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CENTROMERE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FUNCTIONAL ASSESSMENT; GENE DUPLICATION; GENE EXPRESSION REGULATION; HUMAN; MOTOR PERFORMANCE; PATHOGENESIS; PHENOTYPE; PROTEIN PROCESSING; RATING SCALE; SPINAL MUSCULAR ATROPHY; TELOMERE; TREATMENT OUTCOME; WERDNIG HOFFMANN DISEASE;

EID: 55349115073     PISSN: 12107859     EISSN: 18024041     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Kraus J, Hedviǎáková P. Spinální svalové atrofie v dětském věku. Neurol pro praxi 2006; 1: 18-19.
2. Pleasure D. New treatments for denervating diseases. J Child Neurol 2005; 3: 258-262.
3. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004; 1: 59-65.
4. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005; 2: 256-259.
5. Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 1996; 12: 855-859.
6. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, Colitto F et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord 2004; 14: 130-135.
7. Mercuri E, Bertini E, Messina S, Solari A, D'Amico A, Angelozzi C et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007; 1: 51-55.
8. Mercuri E, Messina S, Battini R, Berardinelli A, Boffi P, Bono R et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord 2006; 2: 93-98.
9. Krosschell KJ, Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multicenter research on spinal muscular atrophy. Neuromuscul Disord 2006; 7: 417-426.
10. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 19: 2481-2489.
11. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006; 3: 500-501.
12. http://www.curesma.org
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 9: e45.
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 4: 402-408.
15. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Semin Pediatr Neurol 2006; 2: 121-131.
16. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy and therapeutic prospects. Prog Mol Subcell Biol 2006; 44: 109-132.
17. Riessland M, Brichta L, Hahnen E, Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet 2006; 1: 101-110.
18. Hahnen E, Eyupoglu lY, Brichta L, Haastert K, Trankle C, Siebzehnrubl FA et. al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006; 1: 193-202.
19. Vondracek P, Fajkusova L, Hermanova M, Balintova Z, Seeman P, Mazanec R et al. New Perspectives in the Treatment of Inherited Neuromuscular Disorders: Innovative Ideas for Third Millenium. In: Engels JV (Eds). Focus on Birth Defects Research, New York: Nova Science Publishers 2006: 161-183.
20. www.enmc.org